Related Experiment Videos
The role of third-generation beta-blocking agents in chronic heart failure
M R Bristow1, R L Roden, B D Lowes
1University of Colorado Health Sciences Center, Division of Cardiology, Denver 80262, USA.
Insights
Third-generation beta-blockers offer vasodilation for chronic heart failure (HF) treatment. Ongoing trials will determine if these agents, like carvedilol, outperform older types in managing HF.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Third-generation beta-blockers, initially for hypertension, show promise in chronic heart failure (HF).
- These agents possess vasodilatory properties, improving acute tolerability in HF by reducing left ventricular preload.
- Compounds like carvedilol offer nonselective beta blockade, distinct from selective agents.
Purpose of the Study:
- To evaluate the potential advantages of third-generation beta-blocking agents in chronic heart failure (HF) treatment.
- To compare the comprehensive antiadrenergic profile of third-generation agents with second-generation compounds.
Main Methods:
- Review of pharmacological properties of third-generation beta-blockers.
- Discussion of ongoing and planned clinical trials comparing beta-blocker classes in HF.
Main Results:
- Third-generation beta-blockers exhibit vasodilation and a comprehensive antiadrenergic profile (blocking beta 1 and beta 2 receptors).
- These properties theoretically enhance efficacy in chronic heart failure compared to selective agents.
- Large-scale trial data is pending to confirm these theoretical advantages.
Conclusions:
- Third-generation beta-blockers present a theoretical advantage for chronic heart failure management due to vasodilation and broad receptor blockade.
- Further clinical trials are essential to validate the superiority of third-generation agents over second-generation compounds in HF treatment.
Abstract:
Third-generation beta-blocking agents developed for the hypertension market are proving useful in the treatment of chronic heart failure (HF). These compounds share the ancillary property of vasodilation, which improves acute tolerability by unloading the failing left ventricle at a time when beta-adrenergic withdrawal produces myocardial depression. In the case of carvedilol and bucindolol, this allows for the administration of nonselective beta blockade. Because of blockade of both beta 1 and beta 2 adrenergic receptors as well as other properties, these compounds possess a more comprehensive antiadrenergic profile than second-generation, beta 1-selective compounds. For this and potentially other reasons, third-generation beta-blocking agents have theoretical efficacy advantages that have yet to be demonstrated in large-scale trials. Ongoing trials with either second- or third-generation compounds and one trial directly comparing a compound from each class will provide the answer as to whether third-generation compounds have an advantage in the treatment of chronic HF.